5-FU	Fluorouracil
CA 19-9	Carbohydrate antigen 19-9
CD4+/CD8+	Cluster of differentiation 4/8 (T-lymphocyte subsets)
CE-CT	Contrast-enhanced computed tomography
CI	Confidence interval
COX-2	Cyclooxygenase-2
CR	Complete response
CRC	Colorectal cancer
CTCAE	Common Terminology Criteria for Adverse Events
CXCR4	C-X-C chemokine receptor type 4
CypA	Cyclophilin A
DCR	Disease control rate
dMMR	Mismatch repair deficiency
DoR	Duration of response
ECOG	Eastern Cooperative Oncology Group
EORTC QLQ-C30	European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30
EORTC QLQ-PAN26	European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Pancreatic Cancer Module
ERK	Extracellular signal-regulated kinase
EUS	Endoscopic ultrasound
FDA	Food and Drug Administration
FOLFIRINOX	Folinic acid, fluorouracil, irinotecan, and oxaliplatin (chemotherapy regimen)
FUS/HIFU	Focused ultrasound/high-intensity focused ultrasound
GLOBOCAN	Global Cancer Observatory (global cancer statistics database)
GTP	Guanosine triphosphate
HR	Hazard ratio
HRD	Homologous recombination deficiency
IC50	Half-maximal inhibitory concentration
irAE	Immune-related adverse event
ITT	Intention-to-treat
MAPK	Mitogen-activated protein kinase
MDSCs	Myeloid-derived suppressor cells
mITT	Modified intention-to-treat
MMP	Matrix metalloproteinase
mPDAC	Metastatic pancreatic ductal adenocarcinoma
MSI-H	Microsatellite instability-high
MSS	Microsatellite-stable
MTD	Maximum tolerated dose
N	Number of patients (cohort size)
NALIRIFOX	Liposomal irinotecan, fluorouracil, leucovorin, and oxaliplatin (chemotherapy regimen)
NAT	Neoadjuvant chemotherapy
ncHRD	Non-core homologous recombination deficiency
NCRT	Neoadjuvant chemoradiotherapy
NE	Not evaluable
NF-κB	Nuclear factor kappa-light-chain-enhancer of activated B cells
NIH	National Institutes of Health
NR	Not reached/not reported
NSCLC	Non-small cell lung cancer
ORR	Objective response rate
OS	Overall survival
PARP	Poly(ADP-ribose) polymerase
PASC	Pancreatic adenocarcinoma with squamous differentiation
PD	Progressive disease
PDAC	Pancreatic ductal adenocarcinoma
PD-1	Programmed cell death protein 1
PFS	Progression-free survival
PICO	Population, Intervention, Comparison, Outcome
PK	Pharmacokinetic(s)
PK/PD	Pharmacokinetic-pharmacodynamic
PR	Partial response
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PROSPERO	International Prospective Register of Systematic Reviews
QoL	Quality of life
R0	Microscopically complete resection (negative margin)
RCT	Randomized controlled trial
RECIST	Response Evaluation Criteria in Solid Tumors
RoB 2.0	Cochrane Risk of Bias tool for randomized trials, version 2.0
SAE	Serious adverse event
SD	Stable disease
Sp1	Specificity protein 1
TAMs	Tumor-associated macrophages
TME	Tumor microenvironment
Tmax	Time to maximum plasma concentration
TRAE	Treatment-related adverse event
Tregs	Regulatory T cells